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Accurate blood pressure measurement is critical to properly identify
and treat individuals with hypertension. In 2005, the Canadian Hy-
pertension Education Program produced a revised algorithm to be
used for the diagnosis of hypertension. Subsequent annual reviews of
the literature have identiﬁed 2 major deﬁciencies in the current
diagnostic process. First, auscultatory measurements performed in
routine clinical settings have serious accuracy limitations that have not
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L’exactitude de la mesure de la pression arterielle est essentielle pour
identiﬁer et traiter correctement les individus atteints d’hypertension
arterielle. En 2005, le Programme educatif canadien sur l’hy-
pertension a produit un algorithme revise à utiliser pour le diagnostic
de l’hypertension. Les revisions annuelles subsequentes de la
litterature ont identiﬁe 2 lacunes importantes dans le processus actuel
de diagnostic. Premièrement, les mesures auscultatoires realiseesHypertension affects an estimated 7.3 million Canadians
and is the most common modiﬁable risk factor for death or
numerous organ systems including the brain, heart, eyes,
kidneys, and the peripheral vasculature. Control of hyper-disability in the world.3 If not identiﬁed and treated, hyper-
tension will invariably lead to complications affectingtension in Canada has improved markedly in the past 15 years
with a 5-fold increased rate of control observed, from 13.2%
in 1992 to 64.6% in 2007.4 However, one-third of the hy-
pertensive population remains uncontrolled and 17% remain
unaware that they have hypertension.
Accurate blood pressure (BP) measurement is essential to
properly identify and treat individuals with hypertension.
Ofﬁce BP has been traditionally measured by nurses or doc-
tors using auscultatory methods, with 4 to 5 visits required todian Cardiovascular Society. This is an open access article under the CC BY-
been overcome despite great efforts to educate health care pro-
fessionals over several years. Thus, alternatives to auscultatory mea-
surements should be used. Second, recent data indicate that patients
with white coat hypertension must be identiﬁed earlier in the process
and in a systematic manner rather than on an ad hoc or voluntary
basis so they are not unnecessarily treated with antihypertensive
medications. The economic and health consequences of white coat
hypertension are reviewed. In this article evidence for a revised algo-
rithm to diagnose hypertension is presented. Protocols for home blood
pressure measurement and ambulatory blood pressure monitoring are
reviewed. The role of automated ofﬁce blood pressure measurement is
updated. The revised algorithm strongly encourages the use of vali-
dated electronic digital oscillometric devices and recommends that
out-of-ofﬁce blood pressure measurements, ambulatory blood pres-
sure monitoring (preferred), or home blood pressure measurement,
should be performed to conﬁrm the diagnosis of hypertension.
dans le cadre de la pratique clinique courante montrent de serieuses
limites d’exactitude qui n’ont pas ete surmontees en depit de grands
efforts depuis plusieurs annees pour former les professionnels de la
sante. Par consequent, les solutions de rechange aux mesures aus-
cultatoires soit des mesures electroniques oscillometriques devraient
être utilisees. Deuxièmement, de recentes donnees montrent que les
patients souffrant d’hypertension de sarrau blanc doivent être identi-
ﬁes plus tôt au cours du processus et de manière systematique plutôt
que sur une base ponctuelle ou volontaire aﬁn d’eviter qu’ils ne soient
pas traites inutilement par des antihypertenseurs. Les consequences
sur le plan economique et de la sante de l’hypertension de sarrau
blanc sont decrites dans le texte. Dans le present article, nous
presentons les resultats probants concernant un algorithme revise
pour diagnostiquer l’hypertension arterielle. Nous revisons les proto-
coles de la mesure de la pression arterielle à domicile et du mon-
itorage ambulatoire de la pression arterielle ambulatoire de la
pression arterielle. Nous traitons du rôle des mesures de la pression
arterielle en clinique - oscillometriques en serie. L’algorithme revise
encourage fortement l’utilisation des appareils de mesure oscillome-
triques valides à capteur electronique et lecture numerique, et
recommande que les mesures de la pression arterielle en ambulatoire,
le monitorage ambulatoire de la pression arterielle (preferee) ou la
mesure de la pression arterielle à domicile à domicile soient realisees
pour conﬁrmer le diagnostic d’hypertension.
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were proposed to clinicians in 1984 by the Canadian Hy-
pertension Society and in 1999 by the Canadian Hyperten-
sion Education Program (CHEP) to guide the performance of
these measures.6 In 2005, out-of-ofﬁce measurements using
ambulatory BP measurement (ABPM) or home BP mea-
surement (HBPM) were added to the CHEP algorithm to
complement OBPM.7,8
A reappraisal of the CHEP recommendations to diagnose
hypertensive patients is imperative because of 2 main shortfalls
in the current algorithm. First, ofﬁce auscultatory measure-
ments performed in routine clinical settings have serious
limitations that have not been overcome despite great efforts
to educate health care professionals over several years. Second,
recent data indicate that patients with white coat hypertension
(WCH; ie, not truly hypertensive) should be identiﬁed earlier
in the process and in a systematic manner rather than on an ad
hoc or voluntary basis so they are not unnecessarily treated
with antihypertensive medications.
We present evidence for the need to de-emphasize the use
of routine auscultatory OBPM and encourage use of elec-
tronic digital devices, and evidence for preferentially using
more accurate and reproducible out-of-ofﬁce methods for
earlier and systematic detection of WCH. A revised algorithm
(Fig. 1) for the diagnosis of hypertension is introduced.
HBPM and ABPM protocols will be reviewed, and the role of
automated ofﬁce BP (AOBP) updated.New Algorithm
In our new algorithm we strongly recommend performing
out-of-ofﬁce measurement (ABPM or HBPM) after the ﬁrst
visit, speciﬁcally to identify patients with WCH early in the
process. Another important addition to the algorithm con-
cerns AOBP, which has been shown to reduce the white-coateffect, and, thus the number of patients who will require
further assessment with ABPM or HBPM.9 AOBP implies
multiple oscillometric measurements taken while the patient is
alone in a quiet room. The mean of these measurements is
used to make clinical decisions.
In patients who do not have severely increased BP on visit
1 (180/110 mm Hg), serial standardized OBPMs have been
retained as a potential pathway to arrive at the diagnosis of
hypertension. However, this method is cumbersome because
it requires 4 or 5 visits over 6 months to be truly certain that
the BP level is increased.5 We emphasize that out-of-ofﬁce
measurement is preferred to serial standardized ofﬁce meas-
urementdthe latter should be used only when the resources
(human, technical, or ﬁnancial) to perform out-of-ofﬁce
measurement are not available.Diagnosis of Hypertension in Canada From 1999
to 2005
The approach to the diagnosis of hypertension has evolved
since the Canadian recommendations for the management of
hypertension ﬁrst proposed a systematic approach to diagnose
hypertension based on clinic BP measurement in 1999.10
These initial recommendations indicated that patients who
present with hypertensive urgency (180/105 mm Hg) could
be diagnosed at the ﬁrst visit, patients with increased BP
readings and target organ damage (TOD) could be diagnosed
at/after the third visit, and all other patients with clinic BP
between 140/90 and 180/105 mm Hg would require at least
4 further visits over the next 6 months to be diagnosed with
hypertension. This recommendation was supported by studies
that showed that the number of visits at which clinic BP is
assessed and the duration of the observation period are
important because BP tends to decrease over the course of
several visits.11-15
Figure 1. Diagnostic algorithm for hypertension. BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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Volume 31 2015In 2004, this approach was modiﬁed to allow patients
without TOD and/or increased cardiovascular risk to be
diagnosed at the third visit if clinic BP remained  160/100
mm Hg, because the greatest decrease in BP was shown to
occur between visit 1 and 2.16 If the BP at visit 3 was 140-
159/90-99 mm Hg, up to 3 additional visits over a total
assessment period of 6 months were still required to diagnose
a patient as hypertensive.17-19 In the 2015 algorithm, after 2
visits including the use of out-of-ofﬁce measurements, a
diagnosis of hypertension can be established.
In 2005, the CHEP, recognizing the accumulation of
prognostic evidence in favour of ABPM and HBPM, recom-
mended the addition of these measurement methods as
alternative pathways to expedite the diagnosis of hypertension
after the second visit.8 Since 2005, for uncomplicated patients
(absence of TOD or diabetes mellitus with average BP of 140-
179/90-109 mm Hg after 2 visits), 3 approaches to diagnose
hypertension could be taken: repeated OBPMs over the next
several weeks to months, 24-hour ABPM, or HBPM. Using
the latter 2 out-of-ofﬁce modalities, clinicians could diagnose
uncomplicated hypertension earlier (at the third visit) rather
than taking up to 5 visits over 6 months with repeated
OBPM.Limitations of Routine OBPM
Beneﬁts in terms of decreased morbidity and mortality
from cardiovascular and cerebrovascular causes can be derivedby achieving and sustaining published BP targets. In hyper-
tension management, this largely relies on an accurate mea-
surement and proper subsequent evaluation.20 Many
investigators over the past 4 decades have studied the errors
observed in routine ofﬁce auscultatory measurement, in nurses
and in physicians, because of issues concerning the observer,
the preparation of the patient, the technique, and the device
used.21-29 In addition, studies concerning the knowledge and
practice of doctors and nurses have clearly demonstrated that
there are serious deﬁciencies in all areas despite extensive and
repeated educational programs in the initial education of
health care professionals and through continuous professional
education activities.22,30-35 Accurate OBPM when properly
performed in a standardized method (sometimes called
“research-quality OBPM”), correlates well with ambulatory
measurements and can predict target organ changes.36-38
Unfortunately, there is overwhelming evidence that truly
standardized OBPMs are not usually performed in routine
clinical practice. Indeed, comparisons of BP research-quality
manual BP readings with routine manual BP in a number
of studies have shown that the BP obtained in routine clinical
practice is on average 9/6 mm Hg higher than corresponding
research-quality BP measurements.39,40
“Routine” or “casual” (ie, nonstandardized) BP measure-
ments should never be used to diagnose a patient as hyper-
tensive or to follow a patient’s progress. Examples of
deviations from standardized protocols include among others
measurement of BP in patients without a rest period, while
Cloutier et al. 623
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Although this is not a new recommendation, it is imperative
to stress this issue because nonstandardized BP measurements
are still widely performed.
In place of auscultatory OBPM we strongly encourage the
use of validated electronic digital oscillometric devices. These
devices are preprogrammed to take either single measurements
or an automated series of measurements with averaging of the
results. Electronic oscillometric digital BP measurement has
been available for many years, and has been shown to decrease
a number of errors linked to auscultation measurement
ranging from clinicians’ hearing deﬁcits, rounding errors to
0 or 5, improper use of diaphragm or bell, improper use of
Korotkoff sounds, and rapid deﬂation.41,42 Using published
validation protocols, many devices for clinical and public use
have been found to be accurate and reproducible compared
with research-quality OBPM (www.dableducational.com).
For these reasons, we strongly recommend that electronic
oscillometric digital device methods should be used for
OBPM. Electronic oscillometric digital devices will reduce
terminal digit preference,36,39,43 however, a study performed
in Switzerland demonstrated that terminal digit preference can
still occur with the use of these devices when BP values are
transferred onto case report forms.44 Thus, care must be taken
to record the readings exactly as calculated by the device. The
protocol for OBPM with an electronic oscillometric digital
device is presented in Table 1.
There might be an argument for using an auscultation
method in the ofﬁce in the case of arrhythmias, such as atrial
ﬁbrillation when an automated device might have difﬁculty,
although there is evidence that the auscultation method has
similar difﬁculties.45 Recent published studies have shown
that most electronic oscillometric digital devices measure
systolic BP just as accurately as auscultation methods in pa-
tients with atrial ﬁbrillation, with diastolic BP measured
slightly higher on average.46-48AOBP Can Overcome OBPM Limitations
AOBP measurement is a speciﬁc type of OBPM designed
to overcome some of the limitations of OBPM. Multiple (3-6,
depending on the device) measurements, usually spaced 1
minute apart over 4-7 minutes, are taken while the patient is
alone in a quiet room. The patient must be sitting quietlyTable 1. Ofﬁce BP measurement protocol
1. Measurements should be taken with a sphygmomanometer known to be accurate
2. Choose a cuff with an appropriate bladder size matched to the size of the arm. W
recommended by its manufacturer
3. The patient should be resting comfortably for 5 minutes in the seated position w
4. Place the cuff so that the bladder is centred over the brachial artery. The arm should
will result in an erroneously higher SBP and DBP. The patients’ legs should not
5. There should be no talking during measurement
6. Press the start button. The ﬁrst reading should be discarded and the latter 2 aver
7. BP should also be assessed after 2 minutes of standing (with arm supported) and
Supine BP measurements might also be helpful in the assessment of elderly and
8. Record the BP displayed and the arm used and whether the patient was supine,
9. The seated BP is used to determine and monitor treatment decisions. The stand
modify the treatment
10. BP should be taken in both arms on at least 1 visit and if 1 arm has a consistently h
interpretation
BP, blood pressure; DBP, diastolic BP; SBP, systolic BP.with legs uncrossed, back supported, and with arm supported
at heart level. The proper cuff has to be selected as proposed
by the manufacturer. AOBP devices are preprogrammed to
take serial oscillometric BP measurements and are currently
used in many Canadian clinical settings. To be recognized as
true AOBP, all of these conditions must be met. The mean of
these measurements is used to make clinical decisions.
Commonly used devices include the BpTRU (BpTRU
Medical Devices, Coquitlam, Canada), Omron HEM 907
(Omron Corporation, Kyoto, Japan), and the MicroLife
WatchBP Ofﬁce (Microlife, Widnau, Switzerland).
AOBP provides a more standardized assessment of BP
compared with routine manual ofﬁce measurement and is
more reproducible than manual ofﬁce measurement. Because
the patient is left alone, error introduced by conversing with
the patient during the measurement process is eliminated.49,50
Importantly, compared with manual ofﬁce measurements,
AOBP has repeatedly been demonstrated to correlate closely
with daytime ABPM.9,40,51-54
Furthermore, use of AOBP reduces ofﬁce-induced BP in-
creases (ie, white coat effect) and is associated with a lower
prevalence of masked hypertension.9,53 On the basis of this
evidence, the CHEP Recommendations Task Force endorsed
the use of AOBP for OBPM in 2011.55
Three cross-sectional studies demonstrating high correlations
between AOBP levels and surrogate measures of end-organ
damage (left ventricular mass index, urinary albumin excre-
tion, and carotid intima-medial thickness) have been
published.56-58 Although these surrogate marker studies provide
evidence to support the use of AOBP, additional and more
deﬁnitive data are needed and such studies should be considered
a top research priority. AOBP can be used for assessment of BP
in the ofﬁce although the diagnosis of hypertension cannot be
solely based on this method until high-quality prognostic data
demonstrate strong, independent, and graded relationships be-
tween increasing AOBP levels and incident cardiovascular
morbidity and/or mortality events. When using AOBP, an
average reading of  135/85 can be considered as high.WCH: The Primary Reason to Perform Out-of-
Ofﬁce Measurement
WCH is deﬁned as increased OBPM ( 140/90 mm Hg)
with normal out-of-ofﬁce readings (< 135/85 mm Hg. A validated electronic device should be used
hen using an automated device, select the cuff size using the marks, as
ith back support
be bare and supported with the BP cuff at heart level, because a lower position
be crossed
aged
at times when patients report symptoms suggestive of postural hypotension.
diabetic patients
sitting, or standing. Record the heart rate
ing BP is used to examine for postural hypotension, if present, which might
igher pressure, that arm should be subsequently used for BP measurement and
624 Canadian Journal of Cardiology
Volume 31 2015daytime ABPM or HBPM and/or < 130/80 mm Hg for 24-
hour ABPM). A meta-analysis of 4 population studies found a
prevalence of WCH of 13% with a range of 9%-16%.59
Recently, this prevalence has been challenged and some au-
thors indicate that WCH occurs in up to 30% of subjects with
increased ofﬁce BP readings.60,61 The likelihood of having
WCH is greater in women, older subjects, nonsmokers,
subjects recently diagnosed with hypertension with a limited
number of routine OBPMs, subjects with mild hypertension,
pregnant women, and subjects without evidence of TOD.
The white coat phenomenon has been shown to be reasonably
reproducible.62-64
In 4 meta-analyses, WCH has been shown to have an
overall risk of cardiovascular events similar to
normotension.61,65-67 However, one other meta-analysis of the
International Database of Home BP in Relation to Cardio-
vascular Outcome (IDHOCO) found an increased event rate
among adults with WCH (adjusted hazard ratio, 1.42; 95%
conﬁdence interval, 1.06-1.91).67 It has been suggested that
WCH is associated with a greater risk of developing sustained
hypertension in the next decade, as shown in the Pressione
Arteriose Monitorate E Loro Associazioni (PAMELA) and
Ohasama studies, and that subjects with WCH might have
greater left ventricular mass index compared with normotensive
subjects.68,69 However, in these studies participants with
WCH had other cardiovascular risk factors. Subjects with
WCH have been shown to be more likely to progress to sus-
tained hypertension if they also have high-normal awake
ABPM, additional cardio-metabolic risk factors, or increased
nighttime ABPM.61 The clinical bearing of WCH is not fully
comprehended probably in part because of the presence of
signiﬁcant heterogeneity across studies that assessed its prog-
nosis. Studies differ with respect to population characteristics,
inclusion of treated and/or untreated participants, protocol for
OBPM, reference out-of-ofﬁce BP monitoring method, cutoff
values used, and the duration of follow-up.70
The diagnosis of hypertension using OBPM alone can
misclassify patients who do not have hypertension
(WCH).43,71,72 Every day, more than 1000 people are newly
diagnosed in Canada as hypertensive. BP assessment using
OBPM alone will daily misdiagnose approximately 100 pa-
tients with WCH as hypertensive (36,500 annually).73 This
estimate is conservative and the actual number of patients
with WCH misdiagnosed as hypertensive might be even
higher. Many of these patients will be treated unnecessarily
with antihypertensive medications. Currently, there is no ev-
idence to support pharmacologic treatment of subjects with
WCH.61,74-76 In subjects with WCH, it has been shown that
antihypertensive treatment might decrease OBPM but not
ABPM and second that unnecessary treatment might lead to
partial reduction in white coat effect but with cardiovascular
risk similar to the normotensive comparator group. It has also
been shown in subjects with WCH that the inﬂuence of
treatment on electrocardiogram voltages and on the incidence
of stroke and cardiovascular events is similar to
placebo.61,74-76 Importantly, treated and untreated subjects
with WCH were noted to have similar long-term cardiovas-
cular risk compared with treated and untreated normotensive
subjects, respectively.61
A false diagnosis of hypertension in people with WCH can
also have a signiﬁcant effect on actual or future employability,and workplace issues, such as absenteeism.61 If long-term
antihypertensive treatment is initiated, there will be unnec-
essary costs and potential adverse side effects.
WCH is not entirely benign, therefore it is critical for
patients with WCH to be identiﬁed early so that lifestyle
improvements can be instituted where necessary, and they can
be followed closely. Left untreated, some patients with WCH
will develop hypertension over time68,69 or might have higher
left ventricular mass index compared with normotensive
subjects.77 Patients at greater risk for progression include
those with increased ABPM nighttime average and patients
with high-normal ABPM daytime average, especially the
middle-aged, elderly, and those with associated metabolic risk
factors.
By deﬁnition, OBPM alone cannot determine WCH. The
diagnosis of WCH must be made by comparing out-of-ofﬁce
BP with ofﬁce BP measurements. ABPM and HBPM have
been shown to be effective in diagnosing WCH, and both
methods have been shown to be more strongly associated with
cardiovascular outcomes than OBPM.65,78-87
There is a larger body of evidence for ABPM than HBPM
with respect to prediction of TOD but the evidence for
HBPM has been growing in recent years.88 The diagnostic
agreement between ABPM and HBPM has been shown to be
moderate and it has been suggested that the 2 methods are to
a certain extent complementary.89 ABPM was found to pre-
dict silent cerebrovascular lesions better than HBPM, and
HBPM was more closely associated with the risk of carotid
atherosclerosis than ABPM.90 However, HBPM has been
shown to correlate similarly with ABPM with left ventricular
mass index, but better than OBPM; the evidence for other
TOD markers is limited.91
It has been suggested that HBPM showing borderline
WCH should be conﬁrmed with ABPM88 or with a second
set of HBPM measures.83,92-95 If WCH is shown (ie,
increased OBPM and normal out-of-ofﬁce BP measurement),
the out-of-ofﬁce measurement should be used by health care
practitioners to guide diagnosis and management of
hypertension.Economic Analyses
Several published reports have demonstrated the economic
argument for identifying WCH before making a diagnosis of
hypertension. The most recent systematic review96 identiﬁed
14 published cost-effectiveness studiesd9 clinical trials and 5
model-based decision analyses. Nine studies compared ABPM
with OBPM alone, 4 compared HBPM with OBPM, and 1
compared all 3 methods. In most (8 of 9) studies that
compared ABPM with OBPM investigators found short-term
(lower medication costs from not treating patients with
WCH) and long-term (decreased overall treatment costs)
savings over 1-7 years for hypertension diagnosis conﬁrmation
using ABPM. Only one observational trial97 showed a small
increased cost over 1 year. For HBPM compared with OBPM
the evidence is not as robust but 1 of 2 randomized controlled
trials and 3 of 4 modelling analyses showed a cost beneﬁt. The
only modelling analysis that examined all 3 methods98
concluded, “ABPM is cost effective compared with further
monitoring in the clinic or home for conﬁrming the diagnosis
of hypertension in a population with suspected BP greater
Cloutier et al. 625
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measurement.”
An extensive cost-beneﬁt analysis that examined ABPM
and HBPM vs OBPM for the diagnosis of hypertension was
published by the UK National Institute for Clinical Excel-
lence.99 This analysis concluded that conﬁrming a diagnosis of
hypertension with ABPM instead of OBPM or HBPM was
the most cost-effective option in all age/sex subgroups. In
addition, “In most subgroups ABPM was associated with
higher quality-adjusted life years... as well as lower costs, than
OBPM and HBPM,” (that is, ABPM was the dominant
option). The National Institute for Clinical Excellence
determined that, “Under real world conditions, the use of a
24-hour ABPM device would reduce inappropriate treatment
of patients with WCH. The key driver of cost savings with
ABPM compared with OBPM was hypertension treatment
costs avoided due to more accurate diagnosis (increased
speciﬁcity).”99
In a Canadian context, the Ontario Health Technology
Assessment Centre (OHTAC)100 investigated the cost-
effectiveness of using ABPM to conﬁrm the diagnosis when
OBPM is increased, “considering that over $2.3 billion (Can)
were spent on hypertension in Canada in 2003 (physician,
medication, and laboratory costs), reducing or eliminating the
population of white coat hypertensive individuals who might
inappropriately be treated would potentially result in cost
savings on multiple levels of the health care system.” Based on
their literature review, the OHTAC group found in the short-
term that patients diagnosed using ABPM were more likely to
have control of BP and to discontinue drug therapy. The
OHTAC analysis concluded that the budget effect in Ontario
over the next 5 years (ie, FY2011-FY2015) of providing 24-
hour ABPM to patients only for increased BP readings, or
when BP is not in control, is a cost savings of approximately
$19 million (Can) per year. However, if the test is given once
annually to anyone suspected of having hypertension, the
budget effect is an additional $37 million (Can) per year.
Considering the importance of WCH, the serious limita-
tions of auscultatory OBPM and the importance of identi-
fying hypertension correctly but in a timely manner, it is
crucial at this time to update the diagnostic algorithm.ABPM Method, Reporting, and Interpretation
Method
ABPM has certain advantages, including the requirement
for minimal subject training, and importantly its ability to
provide nighttime BP measurement. This is particularly
important because there is increasing evidence supporting that
nighttime BP is an important predictor of cardiovascular
events, and according to some studies, even more important
than daytime or 24-hour ABPM.78,90,101-104 Several patho-
physiological mechanisms have been proposed to be impli-
cated in the occurrence of cardiovascular events with higher
nighttime BP, including disturbed baroreﬂex sensitivity, al-
terations in the sympathetic modulation of the nighttime BP,
sleep apnea, increased salt sensitivity necessitating a higher BP
at night to drive pressure natriuresis, and nighttime BP is
better standardized than the daytime BP in terms of physical
and mental activity and body position.101Similar to other methods of BP measurement, ABPM must
be performed in a standardized manner. A validated upper
arm device must be used and the appropriate sized cuff29
should be applied to the nondominant arm unless the sys-
tolic BP difference between arms is > 10 mm Hg, in which
case the arm with the highest value obtained should be
used.105 The device should be set to record for a duration of at
least 24 hours,78,106-115 and the measurement frequency set at
20-30 minute intervals during the day, and 30-60 minute
intervals during the night.78,106,107,110,112-114 A patient-
reported diary to deﬁne daytime (awake) and nighttime
(sleep) activities, symptoms, and medication administration is
preferable for study interpretation. Alternatively, predeﬁned
thresholds can be used; for example, deﬁning the daytime
period as 0800 hours to 2200 hours and nighttime as 2200
hours and 0800 hours.
Reporting of ABPM results
The ABPM report, preferably displayed on a single page,
should include all of the individual BP readings (numerically
and graphically), the percentage of successful readings, the
weighted averages for each time frame (daytime, nighttime,
24-hour), and the “dipping” percentage (the percentage
decrease in average nighttime BP from average daytime
BPdnormally between 10% and 20%). The time frame av-
erages can be calculated automatically by the device software,
however there is some difﬁculty making assumptions
regarding the actual awake and sleep time periods for indi-
vidual subjects. Some of the newer devices are equipped with
accelerometers, which might facilitate this in the future. The
report should also include either an automated interpretation
or space for an expert interpretation to be added.
Interpretation of ABPM reports
An ABPM test is considered successful if at least 70% of
the readings are valid and at least 20 daytime readings and 7
nighttime readings are valid. The threshold for diagnosis of
hypertension is a daytime average of  135/85 mm Hg or 24-
hour average of  130/80 mm Hg. Recent literature shows
the critical importance of increased nighttime average and
“nondipping” (ie, < 10% decrease in average nighttime BP
from average daytime BP) as predictors of increased cardio-
vascular disease risk, so the 24-hour average might be more
advantageous because it includes the nighttime period. Many
ABPM reports include a “BP load” percentage for systolic and
diastolic BP, but the evidence supporting the interpretation of
BP load remains limited, and currently it is useful only for
research purposes.HBPM Diagnostic Series
Over the years, increased HBPM use has been undeniably
linked to its powerful predictive value in the occurrence of
cardiovascular events for morbidity and mortality. Prospective
studies have led to a better understanding of the predictive
power of HBPM compared with clinic-based measure-
ments.78,81,87,90,101,102,116 Ward et al. concluded in a recent
meta-analysis of prospective studies in which the relationship
of HBPM with cardiovascular disease was reported that
626 Canadian Journal of Cardiology
Volume 31 2015HBPM is a signiﬁcant predictor of cardiovascular mortality
and cardiovascular events after adjusting for ofﬁce BP.87
HBPM has a singular capacity that differentiates it from
other types of BP measurement. It helps patients to better
control their hypertension117,118 and increases therapeutic
adherence.119 Moreover, the acceptance of the public of
HBPM is remarkable.120 Manufacturers and suppliers have
witnessed explosive sales of HBPM devices.121,122 From a
population health perspective, the motivation of patients to
become involved in follow-up of their chronic diseases such as
hypertension is outstanding news. However, the popularity of
HBPM means that health care professionals need to be pre-
pared to guide patients in best practices. Like other BP
measurement methods, HBPM can be performed incorrectly,
and the risk of reporting bias is increased. However, proper
education on HBPM can improve its performance.123
For several years the CHEP has been publishing recom-
mendations on how to perform HBPM correctly for the
purpose of diagnosing hypertension (HBPM diagnostic series)
and these recommendations remain unchangeddusing a
validated upper arm electronic device with the correct cuff
size, take 2 readings in the morning and evening approxi-
mately 1 minute apart for 7 days. The ﬁrst-day readings are
discarded and the remaining readings are averaged. If the
average is  135/85 mm Hg, a diagnosis of hypertension is
made.Future Revisions of the Algorithm
The role of AOBP in the diagnosis and follow-up of hy-
pertension requires further assessment. This is currently under
study through a CHEP-initiated grant.124 Other issues that
are under review include the need for guidance on how to
identify and diagnose patients with masked hypertension and
whether a lack of nocturnal dipping should be targeted with
bedtime administration of antihypertensive drugs.Conclusion and Recommendations
Many patients in Canada are currently being misdiagnosed
as hypertensive on the basis of increased manual “routine”
ofﬁce BP readings. In the real-world setting of clinical prac-
tice, most of these manual ofﬁce BP readings are poorly
performed using auscultatory techniques.125 Evidence sup-
ports the use of electronic oscillometric digital BP measure-
ments in the ofﬁce setting and the need for out-of-ofﬁce BP
measurements using ABPM or an HBPM diagnostic series to
corroborate increased BP readings performed in the ofﬁce or
clinic setting to properly diagnose hypertension (ie, identify
WCH). Because the cardiovascular risk for WCH has been
shown to be similar to that of normotensive comparator
groups, there is no evidence to support pharmacologic treat-
ment in subjects with WCH at the present time. Mis-
diagnosing patients with WCH as hypertensive might have
important negative implications at the individual and the
health care system level.Funding Sources
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